Pharmacy Utilization Meeting
October 28, 2022

Attendees
Linda Coyle (IMS)
Jennifer Stevens (IMS)
David Angelaszek (IMS)
Chuck May (IMS) – absent
Emily Carver (IMS)
Kevin Ward (Georgia)
Randi Rycroft (Idaho)
Serban Negoita (NCI)
Peggy Adamo (NCI)
Marina Matatova (NCI) – absent
Nadia Howlader (NCI) – absent
Jennifer Hafterson (Seattle)
Tiffany Janes (Seattle)
Kaitlin Akif (NCI)

1. Emily showed the lists of exclusive oncologic agents prescribed prior to dx for 00/01 CTCs.

   - Serban did not have time to review yet but does have Emily's results.

2. Emily reviewed the results of the cumulative duration and quantity for first course agent dispensing events for patients that have a first course dispensing event within the first year after diagnosis (FCOT). We looked specifically at hormone treatments.

   - It was agreed that these quantities are more meaningful when it includes the entire post-dx transaction history for the patient and not just the results in the first year after diagnosis.
   - Kevin noted that he thought the results looked very interesting and valuable for potential research efforts.
   - Emily showed results broken out by year of diagnosis. The results show decrease in time of dx to last hormone with dx year as expected.
   - The results also reflected the fact that the data frequently do not include initial onset of hormone treatments. This was indicated in prior analyses.
   - Emily also showed the differences in the duration of hormone treatment (both time from dx to last first course hormone dispensing event and time from initial first course hormone event to last first course hormone event) for cases with no first course dispensing events in the first year compared to cases with first course dispensing events in the first year. The workgroup is not entirely sure about the explanation for the differences.

3. Documentation going through final edits and updates for new lists from Lois.

4. We reviewed the comments from Lois that histology grouping would be needed for lymphomas, leukemias and endocrine to accurately determine the first course agents for these cancers. Serban commented he might reach out to Jennifer Ruhl to handle the histology groupings.

5. There was discussion about what the next steps would be.

   - Randi: Would be interesting to have the augmented fields available in a SEER*Stat database for researchers to use. She commented it would be helpful and interesting to see how a researcher would utilize the augmented fields.
   - Jennifer H: Commented that she would like to see if data from other pharmacy sources, such as Kaiser, show similar attributes as the CVS/Walgreens data.
   - Kevin: He agreed that would be interesting to see if the UHC-Optum data and Kaiser showed similar results or helped to fill in the gaps we know we have CVS/Walgreens. He also commented that from a registry perspective it would be great to have this in SEER*DMS.
   - Jennifer H agreed it would be good to have in SEER*DMS. Perhaps only viewable by certain users.
   - Linda commented that it should be easy to restrict the users that can see this data in SEER*DMS as we already support that functionality. David, Linda and Jennifer confirmed that adding the augmented fields to DMS should not be an issue. The data can then be included in submission extracts. Estimated effort is a couple of months - in time for February 2023 submission.
   - Linda and David will initiate the process by giving Marina a level of effort for her to review and approve.
   - It was agreed that the immediate effort will be creating datasets to include in SEER*Stat databases.

6. Serban commented that he will be developing a presentation for NCI management that he will give in the next couple months. He may be reaching out to the workgroup for editing assistance and data to share.

7. David commented that the next two meetings fall on holidays. The November 11th meeting will move to November 4th. The November 25th meeting will move to November 18th.